Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medical Countermeasure for Chemical Nerve Agents ALACHUA, Fla. & JERUSALEM--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and [...]
Ology Bioservices will develop the large-scale, process development and manufacturing plan and supply the AnAPN1 vaccine candidate for use in ongoing pre-clinical studies and to prepare for subsequent clinical testing.
Ology Bioservices Strengthens Board of Directors with Appointment of Industry Veterans James M. Robinson and Gerard Cunningham Former Merck & Co. Executives Bring Deep Expertise in Development and Manufacturing of Vaccines and Biologicals [...]
Nanotherapeutics Announces Name Change to Ology Bioservices, Reflecting the Company’s Ongoing Transformation into One of the Top Contract Development and Manufacturing Organizations of Vaccines and Biologics ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc. today announced [...]
ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., a biologics focused contract development and manufacturing organization (CDMO), today announced that Peter H. Khoury, Ph.D., MBA, formerly Senior Vice President and Chief Commercial Officer, has been appointed President and Chief Executive Officer of the Company.
ALACHUA, Fla. & PUNE, India--(BUSINESS WIRE)--Nanotherapeutics Bohumil s.r.o. (a wholly owned subsidiary of Nanotherapeutics, Inc.) and Cyrus Poonawalla Group announced today the final transfer of Nanotherapeutics Bohumil s.r.o.’s vaccine production enterprise located in [...]